# Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC

> **NCT06856278** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Zhejiang Provincial People's Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Anaplastic Throid Carcinoma

## Interventions

- **DRUG:** NKG2D CAR-NK with PD-1 Antibody

## Key facts

- **NCT ID:** NCT06856278
- **Lead sponsor:** Zhejiang Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-22
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-03-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06856278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06856278, "Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06856278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*